Abstract
The search for new therapies against neurodegenerative disorders (NDs) such as Alzheimer (AD) and Parkinson (PD) constitutes a very active area. Although the scientific community has realized great efforts for the study of AD and PD from the most diverse points of view, these diseases remain incurable. Consequently, the design of new and more potent compounds for proteins associated with AD and PD represents nowadays, an objective of major importance. In this sense, the protein known as monoamine oxidase B (MAO-B) constitutes one of the key targets for the search of new drug candidates which could be employed as neuroprotective agents in both anti-AD and anti-PD chemotherapies. The present work is focused on the role of the Quantitative-Structure Activity Relationship (QSAR) analysis and molecular docking (MDock) techniques which have been applied for the discovery of new and promising molecular entities with high inhibitory activity against MAO-B. We also give a brief overview about one of the most potent MAO-B inhibitor drugs: rasagiline. Finally, as contribution to the field, we constructed a QSAR model using artificial neural network (ANN) analysis for the virtual screening of potent MAO-B inhibitors. By realizing a careful inspection of the meaning of the variables in the QSAR-ANN model, new rasagiline bioisosteres were suggested as possible potent MAO-B inhibitors.
Keywords: Alzheimer, artificial neural networks, computer-aided drug design, molecular docking, monoamine Oxidase B, neurodegenerative disorders, neuroprotective, parkinson, QSAR, rasagiline
Current Topics in Medicinal Chemistry
Title:QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres
Volume: 12 Issue: 16
Author(s): Alejandro Speck-Planche and Valeria V. Kleandrova
Affiliation:
Keywords: Alzheimer, artificial neural networks, computer-aided drug design, molecular docking, monoamine Oxidase B, neurodegenerative disorders, neuroprotective, parkinson, QSAR, rasagiline
Abstract: The search for new therapies against neurodegenerative disorders (NDs) such as Alzheimer (AD) and Parkinson (PD) constitutes a very active area. Although the scientific community has realized great efforts for the study of AD and PD from the most diverse points of view, these diseases remain incurable. Consequently, the design of new and more potent compounds for proteins associated with AD and PD represents nowadays, an objective of major importance. In this sense, the protein known as monoamine oxidase B (MAO-B) constitutes one of the key targets for the search of new drug candidates which could be employed as neuroprotective agents in both anti-AD and anti-PD chemotherapies. The present work is focused on the role of the Quantitative-Structure Activity Relationship (QSAR) analysis and molecular docking (MDock) techniques which have been applied for the discovery of new and promising molecular entities with high inhibitory activity against MAO-B. We also give a brief overview about one of the most potent MAO-B inhibitor drugs: rasagiline. Finally, as contribution to the field, we constructed a QSAR model using artificial neural network (ANN) analysis for the virtual screening of potent MAO-B inhibitors. By realizing a careful inspection of the meaning of the variables in the QSAR-ANN model, new rasagiline bioisosteres were suggested as possible potent MAO-B inhibitors.
Export Options
About this article
Cite this article as:
Speck-Planche Alejandro and V. Kleandrova Valeria, QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres, Current Topics in Medicinal Chemistry 2012; 12 (16) . https://dx.doi.org/10.2174/1568026611209061734
DOI https://dx.doi.org/10.2174/1568026611209061734 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calpain-1 and Calpain-2 in the Brain: Dr. Jekill and Mr Hyde?
Current Neuropharmacology Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology Protein Folding, Misfolding and Aggregation: Evolving Concepts and Conformational Diseases
Protein & Peptide Letters From Dual Binding Site Acetylcholinesterase Inhibitors to Multi-Target-Directed Ligands (MTDLs): A Step Forward in the Treatment of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry In Silico Design, Synthesis of Hybrid Combinations: Quercetin Based MAO Inhibitors with Antioxidant Potential
Current Topics in Medicinal Chemistry Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine Hierarchical Profiles of Signaling Pathways and Networks Reveal Two Complementary Pharmacological Mechanisms
CNS & Neurological Disorders - Drug Targets A Review of Agents Patented for their Neuroprotective Properties
Recent Patents on CNS Drug Discovery (Discontinued) Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Intracellular Redox Signaling as Therapeutic Target for Novel Antiviral Strategy
Current Pharmaceutical Design Chemical Composition, Antioxidant, Alpha-glucosidase Inhibitory, Anticholinesterase and Photoprotective Activities of the Aerial Parts of <i>Schinus molle</i> L.
Current Bioactive Compounds Editorial [Pharmacology and Therapeutic Activity of Purinergic Drugs for Disorders of the Nervous System]
CNS & Neurological Disorders - Drug Targets Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders
Current Neuropharmacology Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Genetics of Bladder-Exstrophy-Epispadias Complex (BEEC): Systematic Elucidation of Mendelian and Multifactorial Phenotypes
Current Genomics Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor
Mini-Reviews in Medicinal Chemistry Neuroprotective Mechanisms as Treatment Strategy in Alzheimers disease
Current Medicinal Chemistry - Central Nervous System Agents